BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 11.04.2019 | 18:53

BB Biotech AG concludes its share buyback program and launches a new buyback program

BB BIOTECH AG / Key word(s): Share Buyback
BB Biotech AG concludes its share buyback program and launches a new buyback program

11-Apr-2019 / 18:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media release of April 11, 2019

 

BB Biotech AG concludes its share buyback program and launches a new buyback program

 

Today, April 11, 2019, BB Biotech AG concluded the share buyback program it had initiated on April 12, 2016. During this period no registered shares were repurchased via a second trading line.

The Board of Directors passed a motion to launch a new share repurchase program immediately after the conclusion of this buyback program. Under the new share buyback program, BB Biotech is authorized to repurchase up to 10% of its shares (5 540 000 shares) over a period of 36 months. This decision marks a continuation of the payout policy introduced in 2013.


For further information please contact:

Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht/Zurich
Tanja Chicherio, Tel. +41 44 267 67 00, tch@bellevue.ch

www.bbbiotech.com

 

Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.


11-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Fonds Research 2019: S.E.A. Asian High Yield Bond bietet attraktive Investitionschance

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter auch den S.E.A. Asian High Yield Bond (ISIN: LU1138637738), der eine gute Anlagechance anbietet mit einer Strategie, die kaum reproduzierbar ist. Insbesondere vor dem Hintergrund des anhaltenden Niedrigzinsniveaus sehen wir den Anleihefonds als äußerst attraktive Investitionschance, um nachhaltige und volatilitätsarme Renditen zu erzielen. Wir haben den S.E.A. Asian High Yield Bond mit 4 von 5 Falken eingestuft.

Aktueller Webcast

EQS Group AG

Conference Call zu den Halbjahreszahlen 2019

16. August 2019

Aktuelle Research-Studie

Baumot Group AG

Original-Research: Baumot Group AG (von Montega AG): -

16. August 2019